Lu-Lu Gong1, Bin-Bin Zhao1, Wen-Feng Fan2, Lu-Yu Gong2, Cai-Feng Chen1, Jing-Jun Liu1, Xuan Lu3. 1. MOH Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100000, P.R. China. 2. Department of Infection, Zhongxiang People's Hospital Zhongxiang 431900, Hubei Province, P.R. China. 3. School of Basic Medical Science, Wuhan University Wuhan 430072, P.R. China.
Abstract
PURPOSE: The aim of this study was to identify the correlations of IFN-γ-inducible protein-10 (IP-10) with the risk of chronic hepatitis B (CHB) and the efficacy of interferon therapy in Asians. METHOD: Serum IP-10 levels were assayed using enzyme linked immunosorbent assay (ELISA) in both CHB and control group. CHB group received interferon-α2b treatment to compare the pre-treatment and post-treatment serum IP-10 levels. Relevant studies met predefined inclusion and exclusion criteria were enrolled into further meta-analysis. Stata 12.0 software was applied for data analysis. RESULT: Our case-control study demonstrated that CHB group had evaluated serum IP-10 levels compared with control group (285.7 ± 41.6 pg/mL vs. 79.1 ± 33.8 pg/mL, t = 21.85, P < 0.001. After treatment for 12 weeks, CHB group had remarkably decreased post-treatment serum IP-10 levels than pre-treatment (78.5 ± 20.4 pg/mL vs. 285.7 ± 41.6 pg/mL, t = 33.76, P < 0.001). No significance was observed on post-treatment serum IP-10 levels between CHB and control group (78.5 ± 20.4 pg/mL vs. 78.1 ± 33.8 pg/mL, t = 0.07, P = 0.947). Meta-analysis results demonstrated that serum IP-10 levels in CHB group were obviously higher than healthy controls (SMD = 2.21, 95% CI = 1.55~2.87, P < 0.001). A subgroup based on the HBeAg states revealed that serum IP-10 levels in both HBeAg-positive and HBeAg-negative CHB patients were notably higher than healthy controls (HBeAg-positive: SMD = 2.00, 95% CI = 1.13-2.87, P < 0.001; HBeAg-negative: SMD = 1.34, 95% CI = 0.97-1.72, P < 0.001). CONCLUSION: Serum IP-10 may be correlated with the risk of CHB and the efficiency of interferon therapy, thus IP-10 may be a good biomarker for the diagnosis and treatment of CHB.
PURPOSE: The aim of this study was to identify the correlations of IFN-γ-inducible protein-10 (IP-10) with the risk of chronic hepatitis B (CHB) and the efficacy of interferon therapy in Asians. METHOD: Serum IP-10 levels were assayed using enzyme linked immunosorbent assay (ELISA) in both CHB and control group. CHB group received interferon-α2b treatment to compare the pre-treatment and post-treatment serum IP-10 levels. Relevant studies met predefined inclusion and exclusion criteria were enrolled into further meta-analysis. Stata 12.0 software was applied for data analysis. RESULT: Our case-control study demonstrated that CHB group had evaluated serum IP-10 levels compared with control group (285.7 ± 41.6 pg/mL vs. 79.1 ± 33.8 pg/mL, t = 21.85, P < 0.001. After treatment for 12 weeks, CHB group had remarkably decreased post-treatment serum IP-10 levels than pre-treatment (78.5 ± 20.4 pg/mL vs. 285.7 ± 41.6 pg/mL, t = 33.76, P < 0.001). No significance was observed on post-treatment serum IP-10 levels between CHB and control group (78.5 ± 20.4 pg/mL vs. 78.1 ± 33.8 pg/mL, t = 0.07, P = 0.947). Meta-analysis results demonstrated that serum IP-10 levels in CHB group were obviously higher than healthy controls (SMD = 2.21, 95% CI = 1.55~2.87, P < 0.001). A subgroup based on the HBeAg states revealed that serum IP-10 levels in both HBeAg-positive and HBeAg-negative CHB patients were notably higher than healthy controls (HBeAg-positive: SMD = 2.00, 95% CI = 1.13-2.87, P < 0.001; HBeAg-negative: SMD = 1.34, 95% CI = 0.97-1.72, P < 0.001). CONCLUSION: Serum IP-10 may be correlated with the risk of CHB and the efficiency of interferon therapy, thus IP-10 may be a good biomarker for the diagnosis and treatment of CHB.
Entities:
Keywords:
Chronic hepatitis B; hepatitis B virus; interferon inducible protein 10; interferon-α2b
Authors: K Nishioji; T Okanoue; Y Itoh; S Narumi; M Sakamoto; H Nakamura; A Morita; K Kashima Journal: Clin Exp Immunol Date: 2001-02 Impact factor: 4.330
Authors: Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen Journal: Hepatol Int Date: 2010-02-20 Impact factor: 6.047
Authors: Andréa Marques Vieira da Silva; Lucia Elena Alvarado-Arnez; Tamiris Azamor; Leonardo Ribeiro Batista-Silva; Thyago Leal-Calvo; Ohanna Cavalcanti de Lima Bezerra; Marcelo Ribeiro-Alves; Fernanda de Souza Gomes Kehdy; Patrícia Cristina da Costa Neves; Camilla Bayma; Jane da Silva; Alessandro Fonseca de Souza; Marcelo Muller; Elisabete Ferreira de Andrade; Ana Carolina Magalhães Andrade; Eliane Matos Dos Santos; Janaína Reis Xavier; Maria De Lourdes De Sousa Maia; Rolando Páez Meireles; Hugo Nodarse Cuni; Guilherme Becker Sander; Paulo Dornelles Picon; Denise C S Matos; Milton Ozório Moraes Journal: Front Cell Infect Microbiol Date: 2021-07-07 Impact factor: 5.293